RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nugenerex Immuno-Oncology Stock

Nugenerex Immuno-Oncology ROCE 2024

Nugenerex Immuno-Oncology ROCE

0

Ticker

NUGX

ISIN

US67053X1028

WKN

A2P853

In 2024, Nugenerex Immuno-Oncology's return on capital employed (ROCE) was 0, a 0% increase from the 0 ROCE in the previous year.

Nugenerex Immuno-Oncology Aktienanalyse

What does Nugenerex Immuno-Oncology do?

Nugenerex Immuno-Oncology Inc is an emerging company in cancer research and treatment. It was founded in 2003 by Dr. William J. Garner and is headquartered in San Diego, California. The origins of Nugenerex Immuno-Oncology lie in the exploration of RNA interference (RNAi) and the development of therapeutics for the treatment of cancer and other diseases. In 2006, the company made a groundbreaking discovery by developing a novel technology called "Blank Gene Therapy," which has the potential to revolutionize cancer treatment. Nugenerex Immuno-Oncology is an innovative biotechnology company focused on developing cancer treatments based on the patient's own immune system. The company has a division for cancer research and development and a division for medical services, combining scientific expertise with a global presence. In its research and development division, Nugenerex Immuno-Oncology focuses on developing novel immunological therapies based on "Blank Gene Therapy." These therapies aim to stimulate the patient's immune system to recognize and destroy cancerous cells. In addition to research and development, the company also offers medical services. The medical services division provides patients and healthcare providers worldwide with access to the latest cancer treatments and clinical trials. By collaborating with doctors and hospitals worldwide, patients gain access to innovative cancer treatments tailored to their specific case. The company has several products in development, including a novel immunotherapeutic called "Enrichin." It is based on "Blank Gene Therapy" and aims to stimulate the patient's immune system to recognize and destroy tumor-like cells. Additionally, the company is working on the development of antibody therapeutics and oncolytic viruses to destroy cancer cells. Nugenerex Immuno-Oncology has also formed a partnership with a leading pharmaceutical company to develop therapeutics for multiple sclerosis and other autoimmune diseases. In summary, Nugenerex Immuno-Oncology is an emerging company in cancer research and treatment, focusing on novel immunological therapies. With its products, services, and global presence, it aims to improve the lives of cancer patients worldwide. Nugenerex Immuno-Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Nugenerex Immuno-Oncology's Return on Capital Employed (ROCE)

Nugenerex Immuno-Oncology's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Nugenerex Immuno-Oncology's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Nugenerex Immuno-Oncology's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Nugenerex Immuno-Oncology’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Nugenerex Immuno-Oncology stock

What is the ROCE (Return on Capital Employed) of Nugenerex Immuno-Oncology this year?

The ROCE of Nugenerex Immuno-Oncology is 0 undefined this year.

How has the ROCE (Return on Capital Employed) of Nugenerex Immuno-Oncology developed compared to the previous year?

The ROCE of Nugenerex Immuno-Oncology has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Nugenerex Immuno-Oncology?

A high Return on Capital Employed (ROCE) indicates that Nugenerex Immuno-Oncology has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Nugenerex Immuno-Oncology?

A low ROCE (Return on Capital Employed) can indicate that Nugenerex Immuno-Oncology has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Nugenerex Immuno-Oncology impact the company?

An increase in the ROCE of Nugenerex Immuno-Oncology can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Nugenerex Immuno-Oncology affect the company?

A decrease in ROCE of Nugenerex Immuno-Oncology can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Nugenerex Immuno-Oncology?

Some factors that can affect Nugenerex Immuno-Oncology's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Nugenerex Immuno-Oncology so important for investors?

The ROCE of Nugenerex Immuno-Oncology is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Nugenerex Immuno-Oncology take to improve the ROCE?

To improve the ROCE, Nugenerex Immuno-Oncology can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Nugenerex Immuno-Oncology pay?

Over the past 12 months, Nugenerex Immuno-Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nugenerex Immuno-Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Nugenerex Immuno-Oncology?

The current dividend yield of Nugenerex Immuno-Oncology is .

When does Nugenerex Immuno-Oncology pay dividends?

Nugenerex Immuno-Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nugenerex Immuno-Oncology?

Nugenerex Immuno-Oncology paid dividends every year for the past 0 years.

What is the dividend of Nugenerex Immuno-Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nugenerex Immuno-Oncology located?

Nugenerex Immuno-Oncology is assigned to the '-' sector.

Wann musste ich die Aktien von Nugenerex Immuno-Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nugenerex Immuno-Oncology from 10/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.

When did Nugenerex Immuno-Oncology pay the last dividend?

The last dividend was paid out on 10/7/2024.

What was the dividend of Nugenerex Immuno-Oncology in the year 2023?

In the year 2023, Nugenerex Immuno-Oncology distributed 0 USD as dividends.

In which currency does Nugenerex Immuno-Oncology pay out the dividend?

The dividends of Nugenerex Immuno-Oncology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nugenerex Immuno-Oncology

Our stock analysis for Nugenerex Immuno-Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nugenerex Immuno-Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.